公开(公告)号：US20210380693A1

公开(公告)日：2021-12-09

申请号：US17287838

申请日：2019-10-23

Applicant: Bristol-Myers Squibb Company

Inventor： Sabine MAIER ,  Abderrahim OUKESSOU ,  Nicholas Allan BOTWOOD ,  Kelly L. COVELLO ,  Michael V. MANDOLA ,  Stephen R. LANE

IPC: C07K16/28 ,  A61K31/519 ,  A61K31/555 ,  A61K33/243 ,  A61K31/337 ,  A61P35/00 ,  A61K45/06

Abstract: The disclosure provides a method for treating a subject afflicted with a tumor, e.g., derived from a non-small cell lung cancer (NSCLC), comprising administering to the subject a combination of a (a) chemotherapy, (b) an anti-PD-1 antibody or an anti-PD-L1 antibody, and (c) an anti-CTLA-4 antibody, wherein the chemotherapy is administered for a period of time that is less than the standard.

公开(公告)号：US20210101980A1

公开(公告)日：2021-04-08

申请号：US16499540

申请日：2018-03-30

Applicant: Bristol-Myers Squibb Company

Inventor： Prabhu Seshaiyer BHAGAVATHEESWARAN ,  Nicholas Allan John BOTWOOD ,  Han CHANG ,  Yali FU ,  William J. GEESE ,  George A. GREEN, IV ,  Diane HEALEY ,  Sabine MAIER ,  Faith E. NATHAN ,  Abderrahim OUKESSOU ,  Giovanni SELVAGGI ,  Joseph Daniel SZUSTAKOWSKI

IPC: C07K16/28 ,  C12Q1/6886 ,  A61K39/395 ,  A61P35/00

Abstract: The disclosure provides a method for treating a subject afflicted with a tumor, e.g., lung cancer, having a high tumor mutation burden (TMB) status comprising administering to the subject an immunotherapy, e.g., an anti-PD-1 antibody or antigen-binding portion thereof. The present disclosure also provides a method for identifying a subject suitable for an immunotherapy, e.g., a treatment with an anti-PD-1 antibody or antigen-binding portion thereof, comprising measuring a TMB status of a biological sample of the subject. A high TMB status identifies the patient as suitable for treatment with an anti-PD-1 antibody or antigen-binding portion thereof. The TMB status can be determined by sequencing nucleic acids in the tumor and identifying a genomic alteration, e.g., a somatic nonsynonymous mutation, in the sequenced nucleic acids.

公开(公告)号：US20230295737A1

公开(公告)日：2023-09-21

申请号：US18063015

申请日：2022-12-07

Applicant: Bristol-Myers Squibb Company

Inventor： Prabhu Seshaiyer BHAGAVATHEESWARAN ,  Nicholas Allan John BOTWOOD ,  Han CHANG ,  Yali FU ,  William J. GEESE ,  George A. GREEN ,  Diane HEALEY ,  Sabine MAIER ,  Faith E. NATHAN ,  Abderrahim OUKESSOU ,  Giovanni SELVAGGI ,  Joseph Daniel SZUSTAKOWSKI

IPC: C12Q1/6886

CPC classification number: C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/156

Abstract: The disclosure provides a method for treating a subject afflicted with a tumor, e.g., lung cancer, having a high tumor mutation burden (TMB) status comprising administering to the subject an immunotherapy, e.g., an anti-PD-1 antibody or antigen-binding portion thereof. The present disclosure also provides a method for identifying a subject suitable for an immunotherapy, e.g., a treatment with an anti-PD-1 antibody or antigen-binding portion thereof, comprising measuring a TMB status of a biological sample of the subject. A high TMB status identifies the patient as suitable for treatment with an anti-PD-1 antibody or antigen-binding portion thereof. The TMB status can be determined by sequencing nucleic acids in the tumor and identifying a genomic alteration, e.g., a somatic nonsynonymous mutation, in the sequenced nucleic acids.

公开(公告)号：US20250059610A1

公开(公告)日：2025-02-20

申请号：US18818366

申请日：2024-08-28

Applicant: Bristol-Myers Squibb Company

Inventor： Prabhu Seshaiyer BHAGAVATHEESWARAN ,  Nicholas Allan John BOTWOOD ,  Han CHANG ,  Yali FU ,  William J. GEESE ,  George A. GREEN ,  Diane HEALEY ,  Sabine MAIER ,  Faith E. NATHAN ,  Abderrahim OUKESSOU ,  Giovanni SELVAGGI ,  Joseph Daniel SZUSTAKOWSKI

IPC: C12Q1/6886

Abstract: The disclosure provides a method for treating a subject afflicted with a tumor, e.g., lung cancer, having a high tumor mutation burden (TMB) status comprising administering to the subject an immunotherapy, e.g., an anti-PD-I antibody or antigen-binding portion thereof. The present disclosure also provides a method for identifying a subject suitable for an immunotherapy, e.g., a treatment with an anti-PD-I antibody or antigen-binding portion thereof, comprising measuring a TMB status of a biological sample of the subject. A high TMB status identifies the patient as suitable for treatment with an anti-PD-I antibody or antigen-binding portion thereof. The TMB status can be determined by sequencing nucleic acids in the tumor and identifying a genomic alteration, e.g., a somatic nonsynonymous mutation, in the sequenced nucleic acids.